In a remarkable display of resilience, shares of Cocrystal Pharma Inc. ( COCP ), the $31 million market cap company jumped to a 52-week high, hitting the $3.1 price level. According to InvestingPro data, the stock has shown strong momentum with an increase of 44% since the beginning of the year. This highlight comes as a significant milestone for the company, reflecting a period of robust performance and investor confidence. Over the past year, the stock has witnessed an impressive rise, with Biozone Pharm, its parent company, reporting an incredible one-year change of 70.86%. With analyst price targets ranging from $7 to $10 and a financial health rating of “FAIR” from InvestingProwhich notes that the company has more cash than debt, this increase underscores the positive sentiment surrounding the company’s outlook and the broader biopharma sector’s potential for innovation and growth.
In other recent news, Cocrystal Pharma has made significant adjustments to its executive compensation packages, which include salary increases, bonuses and restricted stock unit (RSU) grants. Co-executive directors James Martin and Dr. The Sam Lees saw their base salaries increase to $416,000, and also received a $200,000 bonus and a grant of 40,000 RSUs. Non-employee directors of the company also received cash grants and RSU grants, with special vesting conditions.
In further development, Cocrystal Pharma has initiated the multiple-escalation phase of its Phase 1 clinical trial for CDI-988, an oral broad-spectrum panviral protease inhibitor. This follows a successful single-escalation phase that was completed in 2024. The company expects peak results from this phase of the CDI-988 study in late 2024 or early 2025.
Regarding the capital structure, Cocrystal Pharma reduced its share capital from 155 million to 101 million shares. Analysts at HC Wainwright maintained a neutral rating on the company, adjusting their target price to $7.00. Meanwhile, Noble Capital maintained its Outperform rating, expressing optimism about the future outcomes of the CC-42344 influenza virus program.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
